Home Cart Sign in  
Chemical Structure| 298708-79-9 Chemical Structure| 298708-79-9

Structure of Bay 41-4109 racemate
CAS No.: 298708-79-9

Chemical Structure| 298708-79-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY-41-4109 racemate can inhibit human hepatitis B virus (HBV) with IC50 of 53 nM.

Synonyms: (±)-BAY 41-4109; BAY41-4109 Racemic

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bay 41-4109 racemate

CAS No. :298708-79-9
Formula : C18H13ClF3N3O2
M.W : 395.76
SMILES Code : O=C(C1=C(C)NC(C2=NC=C(F)C=C2F)=NC1C3=CC=C(F)C=C3Cl)OC
Synonyms :
(±)-BAY 41-4109; BAY41-4109 Racemic
MDL No. :MFCD30729326
InChI Key :FVNJBPMQWSIGJK-UHFFFAOYSA-N
Pubchem ID :9865484

Safety of Bay 41-4109 racemate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
primary human hepatocytes (PHHs) 10 μM 2, 6, or 12 days BAY41 reduced intracellular HBc protein and pgRNA levels but did not change cytoplasmic total pgRNA levels, suggesting that BAY41 increased extracapsid pgRNA levels in the cytoplasm. BAY41 alone did not change intracellular interferon-stimulated gene (ISG) expression levels, but enhanced antiviral ISG induction when combined with IFN-α. Hepatol Commun. 2022 Feb;6(2):281-296
Primary human hepatocytes 100 μM 48 h To evaluate the cytotoxicity of BAY 41-4109, results showed that at high concentrations (up to 100 μM), BAY 41-4109 was significantly more toxic to primary human hepatocytes than GLS4. Antimicrob Agents Chemother. 2013 Nov;57(11):5344-54
HepAD38 cells 25 nM to 100 nM 7 days To evaluate the antiviral activity of BAY 41-4109, results showed that at concentrations ranging from 25 nM to 100 nM, BAY 41-4109 had a weaker effect on inhibiting virus accumulation in the supernatant of HepAD38 cells. Antimicrob Agents Chemother. 2013 Nov;57(11):5344-54
Primary human hepatocytes (PHHs) 263 nM 11 days Evaluate the antiviral activity of BAY41-4109 in HBV-infected primary human hepatocytes, results showed that BAY41-4109 effectively inhibited HBV DNA replication. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17
HepG2 cells 35.4 µM 4 days Evaluate the cytotoxicity of BAY41-4109 on HepG2 cells, results showed that BAY41-4109 was cytotoxic at 35.4 µM. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17
HepG2.2.15 cells 101 nM 6 days Evaluate the inhibitory effect of BAY41-4109 on HBV replication, results showed that BAY41-4109 effectively inhibited HBV DNA replication. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HepAD38 cell transplantation model Oral gavage 60 mg/kg Once daily for 14 days To evaluate the in vivo antiviral efficacy of BAY 41-4109, results showed that at a dose of 60 mg/kg/day, BAY 41-4109 significantly suppressed virus DNA levels, with sustained viral suppression observed both during and after treatment. Antimicrob Agents Chemother. 2013 Nov;57(11):5344-54
Human liver-chimeric mice HBV infection model Oral 40 mg/kg Twice daily for 14 days BAY41 alone did not change intrahepatic ISG expression levels, but the combination of BAY41 and pegIFN-α further enhanced intrahepatic antiviral ISG expression. The serum HBV-DNA levels in mice treated with the combination of BAY41 and pegIFN-α were the lowest observed in all the groups. Hepatol Commun. 2022 Feb;6(2):281-296

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.63mL

2.53mL

1.26mL

25.27mL

5.05mL

2.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories